Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Serplulimab + Chemotherapy in ES-SCLC
NCT05882630Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression Free Survival up to 24 months. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05882630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882630.